Published in Nucleic Acids Res on January 07, 2005
Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides. Nucleic Acids Res (2008) 2.06
miR-122 targeting with LNA/2'-O-methyl oligonucleotide mixmers, peptide nucleic acids (PNA), and PNA-peptide conjugates. RNA (2007) 1.90
Lung delivery studies using siRNA conjugated to TAT(48-60) and penetratin reveal peptide induced reduction in gene expression and induction of innate immunity. Bioconjug Chem (2007) 1.58
Improved cell-penetrating peptide-PNA conjugates for splicing redirection in HeLa cells and exon skipping in mdx mouse muscle. Nucleic Acids Res (2008) 1.52
Intracellular delivery of an anionic antisense oligonucleotide via receptor-mediated endocytosis. Nucleic Acids Res (2008) 1.49
Cell-penetrating peptide conjugates of peptide nucleic acids (PNA) as inhibitors of HIV-1 Tat-dependent trans-activation in cells. Nucleic Acids Res (2005) 1.44
Cellular delivery of small interfering RNA by a non-covalently attached cell-penetrating peptide: quantitative analysis of uptake and biological effect. Nucleic Acids Res (2006) 1.36
Improving the endosomal escape of cell-penetrating peptides and their cargos: strategies and challenges. Pharmaceuticals (Basel) (2012) 1.32
Efficient splicing correction by PNA conjugation to an R6-Penetratin delivery peptide. Nucleic Acids Res (2007) 1.28
The biological effect of an antisense oligonucleotide depends on its route of endocytosis and trafficking. Oligonucleotides (2010) 1.13
MALDI-TOF mass spectral analysis of siRNA degradation in serum confirms an RNAse A-like activity. Mol Biosyst (2006) 1.10
The chemistry and biology of oligonucleotide conjugates. Acc Chem Res (2012) 0.95
Recent developments in peptide-based nucleic acid delivery. Int J Mol Sci (2008) 0.92
Peptide-mediated cellular delivery of oligonucleotide-based therapeutics in vitro: quantitative evaluation of overall efficacy employing easy to handle reporter systems. Curr Pharm Des (2008) 0.91
Antisense and antigene inhibition of gene expression by cell-permeable oligonucleotide-oligospermine conjugates. J Am Chem Soc (2011) 0.90
Carrier-free cellular uptake and the gene-silencing activity of the lipophilic siRNAs is strongly affected by the length of the linker between siRNA and lipophilic group. Nucleic Acids Res (2011) 0.89
Bioconjugation of oligonucleotides for treating liver fibrosis. Oligonucleotides (2007) 0.88
Diels-Alder cycloadditions in water for the straightforward preparation of peptide-oligonucleotide conjugates. Nucleic Acids Res (2006) 0.87
Efficient inhibition of HIV-1 expression by LNA modified antisense oligonucleotides and DNAzymes targeted to functionally selected binding sites. Retrovirology (2007) 0.87
A versatile method for the preparation of conjugates of peptides with DNA/PNA/analog by employing chemo-selective click reaction in water. Nucleic Acids Res (2007) 0.85
Bioconjugates for targeted delivery of therapeutic oligonucleotides. Adv Drug Deliv Rev (2015) 0.83
Cellular uptake and cytotoxicity of drug-peptide conjugates regulated by conjugation site. Bioconjug Chem (2013) 0.83
Peptides used in the delivery of small noncoding RNA. Mol Pharm (2014) 0.83
Bifunctional chimeric fusion proteins engineered for DNA delivery: optimization of the protein to DNA ratio. Biochim Biophys Acta (2009) 0.82
The delivery of therapeutic oligonucleotides. Nucleic Acids Res (2016) 0.82
Creating a ribonuclease T-tat that preferentially recognizes and hydrolyzes HIV-1 TAR RNA in vitro and in vivo. Nucleic Acids Res (2007) 0.80
A role for peptides in overcoming endosomal entrapment in siRNA delivery - A focus on melittin. Biotechnol Adv (2015) 0.79
Covalent conjugation of oligonucleotides with cell-targeting ligands. Bioorg Med Chem (2013) 0.77
Improved Synthesis and In Vitro Evaluation of an Aptamer Ribosomal Toxin Conjugate. Nucleic Acid Ther (2016) 0.75
Regulated portals of entry into the cell. Nature (2003) 15.33
A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem (1997) 6.52
Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat Med (2004) 6.48
Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake. J Biol Chem (2002) 6.01
Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Mol Pharmacol (1992) 3.42
Polyarginine enters cells more efficiently than other polycationic homopolymers. J Pept Res (2000) 3.41
Tackling Tat. J Mol Biol (1999) 3.13
Protein transduction technology. Curr Opin Biotechnol (2002) 2.90
High affinity binding of TAR RNA by the human immunodeficiency virus type-1 tat protein requires base-pairs in the RNA stem and amino acid residues flanking the basic region. J Mol Biol (1993) 2.44
Intracellular distribution of microinjected antisense oligonucleotides. Proc Natl Acad Sci U S A (1991) 2.22
Pathway for polyarginine entry into mammalian cells. Biochemistry (2004) 2.14
Conjugate for efficient delivery of short interfering RNA (siRNA) into mammalian cells. FEBS Lett (2004) 2.13
Visualizing a correlation between siRNA localization, cellular uptake, and RNAi in living cells. Chem Biol (2004) 2.05
Cellular uptake of antisense morpholino oligomers conjugated to arginine-rich peptides. Bioconjug Chem (2004) 1.90
Peptide-linked molecular beacons for efficient delivery and rapid mRNA detection in living cells. Nucleic Acids Res (2004) 1.89
A stepwise dissection of the intracellular fate of cationic cell-penetrating peptides. J Biol Chem (2004) 1.72
A new peptide vector for efficient delivery of oligonucleotides into mammalian cells. Nucleic Acids Res (1997) 1.67
Biochemical and functional interactions between HIV-1 Tat protein and TAR RNA. Arch Biochem Biophys (1999) 1.66
Pseudo--half-knot formation with RNA. Science (1992) 1.58
Uptake of analogs of penetratin, Tat(48-60) and oligoarginine in live cells. Biochem Biophys Res Commun (2003) 1.57
Stearylated arginine-rich peptides: a new class of transfection systems. Bioconjug Chem (2001) 1.53
Cell penetrating PNA constructs regulate galanin receptor levels and modify pain transmission in vivo. Nat Biotechnol (1998) 1.44
Inhibition of HIV-LTR gene expression by oligonucleotides targeted to the TAR element. Nucleic Acids Res (1991) 1.37
A peptide nucleic acid-nuclear localization signal fusion that mediates nuclear transport of DNA. Nat Biotechnol (1999) 1.37
Inhibition of HIV-1 Tat-dependent trans activation by steric block chimeric 2'-O-methyl/LNA oligoribonucleotides. Biochemistry (2001) 1.33
Cell-dependent differential cellular uptake of PNA, peptides, and PNA-peptide conjugates. Antisense Nucleic Acid Drug Dev (2002) 1.32
Conjugates of antisense oligonucleotides with the Tat and antennapedia cell-penetrating peptides: effects on cellular uptake, binding to target sequences, and biologic actions. Pharm Res (2002) 1.31
Downregulation of amyloid precursor protein inhibits neurite outgrowth in vitro. J Cell Biol (1995) 1.28
Downregulation of Cu/Zn superoxide dismutase leads to cell death via the nitric oxide-peroxynitrite pathway. J Neurosci (1996) 1.24
Peptide-mediated cell delivery: application in protein target validation. Curr Opin Pharmacol (2002) 1.23
Getting hydrophilic compounds into cells: lessons from homeopeptides. Curr Opin Neurobiol (1996) 1.16
Peptide-mediated cellular delivery of antisense oligonucleotides and their analogues. Cell Mol Life Sci (2003) 1.15
Effects in live cells of a c-myc anti-gene PNA linked to a nuclear localization signal. Nat Biotechnol (2000) 1.10
Improved biological activity of antisense oligonucleotides conjugated to a fusogenic peptide. Nucleic Acids Res (1994) 1.10
Antisense morpholino-oligomers directed against the 5' end of the genome inhibit coronavirus proliferation and growth. J Virol (2004) 1.09
Enhancing membrane permeability by fatty acylation of oligoarginine peptides. Chembiochem (2004) 1.06
Oligonucleotide analogue interference with the HIV-1 Tat protein-TAR RNA interaction. Nucleosides Nucleotides Nucleic Acids (2001) 1.05
Characterization of peptide-oligonucleotide heteroconjugates by mass spectrometry. Nucleic Acids Res (1996) 1.04
Inhibition of Tat-mediated transactivation of HIV-1 LTR transcription by polyamide nucleic acid targeted to TAR hairpin element. Biochemistry (2000) 1.03
Anti-TAR polyamide nucleotide analog conjugated with a membrane-permeating peptide inhibits human immunodeficiency virus type 1 production. J Virol (2002) 1.03
Synthesis of peptide-oligonucleotide conjugates with single and multiple peptides attached to 2'-aldehydes through thiazolidine, oxime, and hydrazine linkages. Bioconjug Chem (2002) 1.00
LNA/DNA chimeric oligomers mimic RNA aptamers targeted to the TAR RNA element of HIV-1. Nucleic Acids Res (2004) 0.97
Cellular uptake and intracellular fate of antisense oligonucleotides. Curr Opin Mol Ther (2003) 0.96
Antisense inhibition of P-glycoprotein expression using peptide-oligonucleotide conjugates. Biochem Pharmacol (2000) 0.95
Efficient conjugation of peptides to oligonucleotides by "native ligation". J Org Chem (2000) 0.93
A structure-activity study of the inhibition of HIV-1 Tat-dependent trans-activation by mixmer 2'-O-methyl oligoribonucleotides containing locked nucleic acid (LNA), alpha-L-LNA, or 2'-thio-LNA residues. Oligonucleotides (2003) 0.92
Oligonucleotide inhibition of the interaction of HIV-1 Tat protein with the trans-activation responsive region (TAR) of HIV RNA. Biochim Biophys Acta (1999) 0.91
Cell-penetrating peptides do not cross mitochondrial membranes even when conjugated to a lipophilic cation: evidence against direct passage through phospholipid bilayers. Biochem J (2004) 0.91
Loop-loop interaction of HIV-1 TAR RNA with N3'-->P5' deoxyphosphoramidate aptamers inhibits in vitro Tat-mediated transcription. Proc Natl Acad Sci U S A (2002) 0.91
2'-O-methyl-RNA hairpins generate loop-loop complexes and selectively inhibit HIV-1 Tat-mediated transcription. Biochemistry (2002) 0.90
Targeting the HIV trans-activation responsive region--approaches towards RNA-binding drugs. Chembiochem (2003) 0.87
3'-methylphosphonate-modified oligo-2'-O-methylribonucleotides and their Tat peptide conjugates: uptake and stability in mouse fibroblasts in culture. Bioconjug Chem (2004) 0.86
Total stepwise solid-phase synthesis of oligonucleotide-(3'-->N)-peptide conjugates. Org Lett (2002) 0.82
A concise method for the preparation of peptide and arginine-rich peptide-conjugated antisense oligonucleotide. Bioconjug Chem (2003) 0.82
Peptide-oligonucleotide phosphorothioate conjugates with membrane translocation and nuclear localization properties. Bioconjug Chem (1999) 0.81
A convenient solid-phase method for synthesis of 3'-conjugates of oligonucleotides. Bioconjug Chem (2001) 0.81
Cellular delivery of oligonucleotides by synthetic import peptide carrier. Pharm Res (1997) 0.77
Control of intracellular delivery of oligonucleotides by signal peptides and genetic expression in human cells. Nucleic Acids Symp Ser (Oxf) (2004) 0.77
miR-122 targeting with LNA/2'-O-methyl oligonucleotide mixmers, peptide nucleic acids (PNA), and PNA-peptide conjugates. RNA (2007) 1.90
Expression analysis in multiple muscle groups and serum reveals complexity in the microRNA transcriptome of the mdx mouse with implications for therapy. Mol Ther Nucleic Acids (2012) 1.53
Improved cell-penetrating peptide-PNA conjugates for splicing redirection in HeLa cells and exon skipping in mdx mouse muscle. Nucleic Acids Res (2008) 1.52
Cell penetrating peptide conjugates of steric block oligonucleotides. Adv Drug Deliv Rev (2007) 1.47
Cell-penetrating peptide conjugates of peptide nucleic acids (PNA) as inhibitors of HIV-1 Tat-dependent trans-activation in cells. Nucleic Acids Res (2005) 1.44
Pip6-PMO, A New Generation of Peptide-oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity for DMD Treatment. Mol Ther Nucleic Acids (2012) 1.41
Efficient inhibition of miR-155 function in vivo by peptide nucleic acids. Nucleic Acids Res (2010) 1.41
Endosome trapping limits the efficiency of splicing correction by PNA-oligolysine conjugates. J Control Release (2005) 1.38
RNA-targeted splice-correction therapy for neuromuscular disease. Brain (2010) 1.36
Pip5 transduction peptides direct high efficiency oligonucleotide-mediated dystrophin exon skipping in heart and phenotypic correction in mdx mice. Mol Ther (2011) 1.32
Efficient splicing correction by PNA conjugation to an R6-Penetratin delivery peptide. Nucleic Acids Res (2007) 1.28
RNA targeting with peptide conjugates of oligonucleotides, siRNA and PNA. Blood Cells Mol Dis (2006) 1.22
Diaphragm rescue alone prevents heart dysfunction in dystrophic mice. Hum Mol Genet (2010) 1.19
MALDI-TOF mass spectral analysis of siRNA degradation in serum confirms an RNAse A-like activity. Mol Biosyst (2006) 1.10
MicroRNA fate upon targeting with anti-miRNA oligonucleotides as revealed by an improved Northern-blot-based method for miRNA detection. RNA (2011) 1.02
A chemical view of oligonucleotides for exon skipping and related drug applications. Nucleic Acid Ther (2013) 1.00
Chemical structure requirements and cellular targeting of microRNA-122 by peptide nucleic acids anti-miRs. Nucleic Acids Res (2011) 1.00
Synthesis of peptide-oligonucleotide conjugates with single and multiple peptides attached to 2'-aldehydes through thiazolidine, oxime, and hydrazine linkages. Bioconjug Chem (2002) 1.00
Optimization of peptide nucleic acid antisense oligonucleotides for local and systemic dystrophin splice correction in the mdx mouse. Mol Ther (2010) 0.98
PepFect 14, a novel cell-penetrating peptide for oligonucleotide delivery in solution and as solid formulation. Nucleic Acids Res (2011) 0.97
Peptide-mediated Cell and In Vivo Delivery of Antisense Oligonucleotides and siRNA. Mol Ther Nucleic Acids (2012) 0.95
Disulfide conjugation of peptides to oligonucleotides and their analogs. Curr Protoc Nucleic Acid Chem (2006) 0.93
In vitro evaluation of novel antisense oligonucleotides is predictive of in vivo exon skipping activity for Duchenne muscular dystrophy. J Gene Med (2010) 0.93
A structure-activity study of the inhibition of HIV-1 Tat-dependent trans-activation by mixmer 2'-O-methyl oligoribonucleotides containing locked nucleic acid (LNA), alpha-L-LNA, or 2'-thio-LNA residues. Oligonucleotides (2003) 0.92
A peptide-based dendrimer that enhances the splice-redirecting activity of PNA conjugates in cells. Bioconjug Chem (2009) 0.92
Cell-penetrating peptides do not cross mitochondrial membranes even when conjugated to a lipophilic cation: evidence against direct passage through phospholipid bilayers. Biochem J (2004) 0.91
Loop-loop interaction of HIV-1 TAR RNA with N3'-->P5' deoxyphosphoramidate aptamers inhibits in vitro Tat-mediated transcription. Proc Natl Acad Sci U S A (2002) 0.91
Pyrenemethyl ara-uridine-2'-carbamate: a strong interstrand excimer in the major groove of a DNA duplex. Chembiochem (2003) 0.90
2'-O-methyl-RNA hairpins generate loop-loop complexes and selectively inhibit HIV-1 Tat-mediated transcription. Biochemistry (2002) 0.90
Lipoplex and peptide-based strategies for the delivery of steric-block oligonucleotides. Int J Pharm (2007) 0.89
Dual Myostatin and Dystrophin Exon Skipping by Morpholino Nucleic Acid Oligomers Conjugated to a Cell-penetrating Peptide Is a Promising Therapeutic Strategy for the Treatment of Duchenne Muscular Dystrophy. Mol Ther Nucleic Acids (2012) 0.89
Synthesis and biological activity of phosphonoacetate- and thiophosphonoacetate-modified 2'-O-methyl oligoribonucleotides. Org Biomol Chem (2011) 0.89
Targeting the HIV-1 RNA leader sequence with synthetic oligonucleotides and siRNA: chemistry and cell delivery. Biochim Biophys Acta (2005) 0.88
Exploiting cell surface thiols to enhance cellular uptake. Trends Biotechnol (2012) 0.88
Overview of alternative oligonucleotide chemistries for exon skipping. Methods Mol Biol (2012) 0.88
Potent and sustained cellular inhibition of miR-122 by lysine-derivatized peptide nucleic acids (PNA) and phosphorothioate locked nucleic acid (LNA)/2'-O-methyl (OMe) mixmer anti-miRs in the absence of transfection agents. Artif DNA PNA XNA (2012) 0.87
Synthesis and splice-redirecting activity of branched, arginine-rich peptide dendrimer conjugates of peptide nucleic acid oligonucleotides. Bioconjug Chem (2010) 0.87
Use of carbonyl group addition--elimination reactions for synthesis of nucleic acid conjugates. Bioconjug Chem (2005) 0.86
Cellular trafficking determines the exon skipping activity of Pip6a-PMO in mdx skeletal and cardiac muscle cells. Nucleic Acids Res (2013) 0.86
Increased RNAi is related to intracellular release of siRNA via a covalently attached signal peptide. RNA (2009) 0.85
Antiviral activity of steric-block oligonucleotides targeting the HIV-1 trans-activation response and packaging signal stem-loop RNAs. Nucleosides Nucleotides Nucleic Acids (2005) 0.85
A bi-functional siRNA construct induces RNA interference and also primes PCR amplification for its own quantification. Nucleic Acids Res (2005) 0.84
Oligonucleotide analogs as antiviral agents. Curr Opin Mol Ther (2006) 0.84
Chemical modifications to improve the cellular uptake of oligonucleotides. Curr Top Med Chem (2007) 0.84
Synthesis of oligonucleotide 2'-conjugates via amide bond formation in solution. Bioorg Med Chem Lett (2004) 0.83
Peptide-based delivery of steric-block PNA oligonucleotides. Methods Mol Biol (2009) 0.83
Hexitol nucleic acid-containing aptamers are efficient ligands of HIV-1 TAR RNA. Biochemistry (2005) 0.83
Parallel synthesis of cell-penetrating peptide conjugates of PMO toward exon skipping enhancement in Duchenne muscular dystrophy. Nucleic Acid Ther (2014) 0.83
Systematic screening of LNA/2'-O-methyl chimeric derivatives of a TAR RNA aptamer. FEBS Lett (2007) 0.82
Tricyclo-DNA containing oligonucleotides as steric block inhibitors of human immunodeficiency virus type 1 tat-dependent trans-activation and HIV-1 infectivity. Oligonucleotides (2007) 0.82
Total stepwise solid-phase synthesis of oligonucleotide-(3'-->N)-peptide conjugates. Org Lett (2002) 0.82
Development of a general methodology for labelling peptide-morpholino oligonucleotide conjugates using alkyne-azide click chemistry. Chem Commun (Camb) (2013) 0.81
Splice-correcting oligonucleotides restore BTK function in X-linked agammaglobulinemia model. J Clin Invest (2014) 0.80
PNA-peptide conjugates as intracellular gene control agents. Nucleic Acids Symp Ser (Oxf) (2008) 0.80
Parallel synthesis and splicing redirection activity of cell-penetrating peptide conjugate libraries of a PNA cargo. Org Biomol Chem (2013) 0.80
Steric inhibition of human immunodeficiency virus type-1 Tat-dependent trans-activation in vitro and in cells by oligonucleotides containing 2'-O-methyl G-clamp ribonucleoside analogues. Nucleic Acids Res (2003) 0.79
Peptide-based in vivo delivery agents for oligonucleotides and siRNA. Nucleic Acid Ther (2012) 0.79
LNA and alpha-L-LNA: towards therapeutic applications. Nucleosides Nucleotides Nucleic Acids (2003) 0.78
Inhibition of HIV-1 replication by oligonucleotide analogues directed to the packaging signal and trans-activating response region. Antivir Chem Chemother (2006) 0.78
Anti-HIV activity of steric block oligonucleotides. Ann N Y Acad Sci (2006) 0.77
Chemical methods for peptide-oligonucleotide conjugate synthesis. Methods Mol Biol (2005) 0.77
Oligonucleotides containing 2'-O-[2-(2,3-dihydroxypropyl)amino-2-oxoethyl]uridine as suitable precursors of 2'-aldehyde oligonucleotides for chemoselective ligation. Bioorg Med Chem (2005) 0.76
Splice redirection as a convenient assay to monitor CPP-ON efficiency and mechanism. Methods Mol Biol (2011) 0.76
Peptide nanoparticle delivery of charge-neutral splice-switching morpholino oligonucleotides. Nucleic Acid Ther (2015) 0.75
Preparation of 2'-hydrazino oligonucleotides and their reaction with aldehydes and 1,3-diketones. Nucleosides Nucleotides Nucleic Acids (2007) 0.75
Comparative studies of tricyclo-DNA- and LNA-containing oligonucleotides as inhibitors of HIV-1 gene expression. Nucleosides Nucleotides Nucleic Acids (2007) 0.75
Total stepwise solid-phase peptide-oligonucleotide conjugate synthesis on macroporous polystyrene. Nucleosides Nucleotides Nucleic Acids (2003) 0.75
2'-Hydrazine oligonucleotides: synthesis and efficient conjugation with aldehydes. Nucleic Acids Symp Ser (Oxf) (2005) 0.75
Incorporation of side-chain groups of basic amino acids into oligonucleotides via the 2'-position of uridine. Nucleic Acids Symp Ser (Oxf) (2005) 0.75
2'-Functionalized nucleic acids as structural tools in molecular biology. IUBMB Life (2004) 0.75
Corrigendum: Identification of novel, therapy-responsive protein biomarkers in a mouse model of Duchenne muscular dystrophy by aptamer-based serum proteomics. Sci Rep (2016) 0.75
The synthesis of 2'-O-methyl G-clamp containing oligonucleotides and their inhibition of the HIV-1 Tat-TAR interaction. Nucleosides Nucleotides Nucleic Acids (2003) 0.75
(R)-2,4-Dihydroxybutyramide seco-pseudonucleosides: new versatile homochiral synthons for synthesis of modified oligonucleotides. Org Lett (2002) 0.75
In Vitro Assays to Assess Exon Skipping in Duchenne Muscular Dystrophy. Methods Mol Biol (2015) 0.75
Nucleic acids: new life, new materials. Org Biomol Chem (2013) 0.75
Uridine 2'-carbamates: facile tools for oligonucleotide 2'-functionalization. Curr Protoc Nucleic Acid Chem (2004) 0.75
Steric block high affinity oligonucleotide analogues: a new tool for mapping RNA-protein binding sites. Nucleosides Nucleotides Nucleic Acids (2008) 0.75
1,2-Diol and hydrazide phosphoramidites for solid-phase synthesis and chemoselective ligation of 2'-modified oligonucleotides. Nucleosides Nucleotides Nucleic Acids (2003) 0.75